<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3755">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058029</url>
  </required_header>
  <id_info>
    <org_study_id>GS-200-002</org_study_id>
    <nct_id>NCT03058029</nct_id>
  </id_info>
  <brief_title>Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and Metformin-treated Type 2 Diabetes</brief_title>
  <acronym>LIGHT-UP</acronym>
  <official_title>A Randomize, Double-blind, Placebo-controlled, Parallel-group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and Met Forming-treated Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelesis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelesis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will asses the effect of Gelesis200 on body weight in overweight and obese
      subjects with prediabetes and metformin-treated type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight (percent change)</measure>
    <time_frame>Up to 31 weeks</time_frame>
    <description>Placebo-adjusted weight loss of ≥3.0% from baseline up to 31 weeks in prediabetic subjects or ≥2.0% in diabetic subjects on Gelesis200.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight responders (≥5.0% weight loss)</measure>
    <time_frame>Up to 31 weeks</time_frame>
    <description>Weight loss of &gt;5.0% in at least 35% of prediabetic subjects or in at least 25% of diabetic subjects on Gelesis200.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with change in HbA1c status (normal, impaired, or diabetic)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with change in FPG status (normal, impaired, or diabetic)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects with change in post-OGTT plasma glucose status (normal, impaired, or diabetic)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in post-OGTT plasma glucose</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change or percent change in post-OGTT serum insulin AUC</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting serum insulin</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Gelesis200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three (3) Gelesis200 capsules (2.10 gram (g)) three (3) times per day (id est (i.e.), breakfast, lunch, and dinner)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Gelesis200</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three (3) placebo capsules at breakfast, and three (3) Gelesis200 capsules (2.10 g) two (2) times per day (i.e., lunch and dinner)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three (3) placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gelesis200</intervention_name>
    <arm_group_label>Gelesis200</arm_group_label>
    <arm_group_label>Placebo and Gelesis200</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) ≥27 and ≤40 kilogram (kg)/meter (M)2 with body weight &lt;120 kg

          -  Prediabetic subjects with FPG ≥100 milligram (mg)/deciliter (dL) and &lt;126 mg/dL [≥5.6
             millimole (mmol)/liter (L) and &lt;7.0 mmol/L] at both Screening Visits with HbA1c ≤6.4%
             [if only 1 value is within this range, the other value should not be ≥126 mg/dL (≥7.0
             mmol/L) and HbA1c should be ≥5.7% and ≤6.4%] or metformin-treated diabetic subjects
             with FPG ≥70 mg/dL and ≤270 mg/dL (≥3.9 mmol/L and ≤15.1 mmol/L) at both Screening
             Visits.

          -  Fasting serum insulin &lt;20 microunit (mU)/milliliter (mL) at both Screening Visits in
             prediabetic subjects.

          -  Ability to follow verbal and written instructions

          -  Consent obtained via signed ICF

        Exclusion Criteria:

          -  Pregnancy [or positive serum or urine pregnancy test(s) in females of childbearing
             potential]

          -  Absence of medically approved contraception in females of childbearing potential
             [exempli gratia (e.g.), hysterectomy, oral contraceptive medications, intrauterine
             device combined with a barrier method, two (2) combined barrier methods such as
             diaphragm and condom or spermicide, or condom and spermicide; bilateral tubal
             ligation and vasectomy are acceptable contraceptive methods when combined with
             another single method from above]

          -  History of allergic reaction to carboxymethylcellulose (CMC), citric acid,
             maltodextrin, gelatin, or titanium dioxide

          -  Participation in a weight loss study within the past twelve (12) months

          -  Administration of Gelesis100 or Gelesis200 in a previous study

          -  Administration of investigational products within one (1) month prior to Screening
             Visit

          -  Smoking cessation within six (6) months prior to Screening Visit or considering
             smoking cessation during the study

          -  Anticipated surgical intervention during the study period

          -  Known Type 1 Diabetes

          -  History of eating disorders including binge eating (except for mild binge eating) or
             emesis ≥2/week from any cause

          -  Weight change &gt;3% within three (3) months prior to and during the Screening period

          -  Supine systolic blood pressure (SBP) &gt;160 millimeters of mercury (mmHg) and/or supine
             diastolic blood pressure (DBP) &gt;95 mmHg

          -  Angina, coronary bypass, or myocardial infarction within six (6) months prior to
             Screening Visit

          -  History of swallowing disorders

          -  Esophageal anatomic abnormalities (e.g., webs, diverticuli, rings)

          -  History of gastroesophageal reflux disease

          -  History of gastric or duodenal ulcer

          -  History of gastroparesis (e.g., chronic nausea, vomiting ≥2 occurrences per week,
             heartburn, etc.)

          -  History of gastric bypass or any other gastric surgery

          -  History of small bowel resection (except if related to appendectomy)

          -  History of intestinal stricture (e.g., Crohn's disease)

          -  History of intestinal obstruction or high risk of intestinal obstruction, including
             suspected small bowel adhesions

          -  History of abdominal radiation treatment

          -  History of pancreatitis within the past 12 months

          -  History of malabsorption

          -  Laxative users, except those on stable doses within one (1) month prior to Screening
             Visit

          -  History of hepatitis B or C

          -  History of human immunodeficiency virus (HIV)

          -  History of cancer within the past five (5) years (except adequately-treated localized
             basal cell skin cancer or in situ uterine cervical cancer)

          -  Any other clinically significant disease interfering with the assessments of
             Gelesis200 (e.g., disease requiring corrective treatment, potentially leading to
             study discontinuation)

          -  Abnormal serum thyroid-stimulating hormone (TSH)

          -  HbA1c &gt;8.5% (&gt;69 mmol/mole (mol))

          -  Serum low-density lipoprotein (LDL) cholesterol ≥160 mg/dL (≥4.15 mmol/L)

          -  Serum triglycerides ≥350 mg/dL (≥3.96 mmol/L)

          -  Positive test for drugs of abuse in the urine

          -  Any relevant biochemical abnormality interfering with the assessments of Gelesis200

          -  Anti-obesity medications (including herbal preparations) within one (1) month prior
             to Screening Visit

          -  Systemic corticosteroids within one (1) month prior to Screening Visit

          -  Thyroid hormones or preparations within one (1) month prior to Screening Visit
             [except stable dose of replacement therapy for at least two (2) months]

          -  TSH suppression therapy for thyroid cancer

          -  Estrogen within one (1) month prior to Screening Visit [except stable dose of
             replacement therapy or contraceptives for at least one (1) month]

          -  Any other medication known to cause weight loss or weight gain within one (1) month
             prior to Screening Visit

          -  Antidiabetic medications within one (1) month prior to Screening Visit [except stable
             doses of metformin for at least one (1) month in subjects with Type 2 Diabetes]

          -  Change in medications treating hypertension within one (1) month prior to Screening
             Visit

          -  Change in medications treating dyslipidemia within one (1) month prior to Screening
             Visit

          -  Anticipated requirement for use of prohibited concomitant medications

          -  Any other condition that, in the opinion of the Investigator or Sponsor, would
             interfere with the subject's ability to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://gelesis.com/clinical-trials.php</url>
    <description>Gelesis Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
